-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, BPT0tVFoKt3oufzgKJ5+GcBeeGEnhIkafnAn/+hNdNbDJUI5hK8L4bdc6tpIsBdw YWr2T5M5lyPQI1D3PpuZIg== 0000950103-06-002135.txt : 20060919 0000950103-06-002135.hdr.sgml : 20060919 20060919101826 ACCESSION NUMBER: 0000950103-06-002135 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20060915 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20060919 DATE AS OF CHANGE: 20060919 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Shire plc CENTRAL INDEX KEY: 0000936402 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-29630 FILM NUMBER: 061097077 BUSINESS ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 ZIP: - BUSINESS PHONE: 1264333455 MAIL ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 ZIP: - FORMER COMPANY: FORMER CONFORMED NAME: SHIRE PHARMACEUTICALS GROUP PLC DATE OF NAME CHANGE: 19980302 8-K 1 dp03521_8k.htm




UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT


Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 15, 2006

Shire plc

(Exact name of registrant as specified in its charter)

England and Wales

(State or other jurisdiction of incorporation)

0-29630		98-0484822
(Commission File Number)		(IRS Employer Identification No.)

Hampshire International Business Park, Chineham, Basingstoke,
Hampshire RG24 8EP England

(Address of principal executive offices)	(Zip code)

Registrant’s telephone number, including area code	44 1256 894 000

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events

Shire plc has issued the press releases attached as Exhibit 99.01 and Exhibit 99.02 which are incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits

	(c)	Exhibits. The following exhibits are filed herewith:

99.01		Press Release dated September 15, 2006
99.02		Press Release dated September 18, 2006

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SHIRE PLC

By:	/s/ A C Russell

	Name:	Angus Russell
	Title:	Chief Financial Officer

Dated: September 18, 2006

EXHIBIT INDEX

Number	Description

99.01	Press Release dated September 15, 2006
99.02	Press Release dated September 18, 2006

EX-99.1 2 dp03521_ex9901.htm

	Exhibit 99.01
Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com

Press Release

15 September 2006

Shire plc ("Shire")

Purchase of Shares by Employee Benefit Trust

Shire has been notified that on 15 September 2006, the Shire plc Employee Benefit Trust (the “Trust”) purchased 135,000 Ordinary Shares of Shire plc (“Shares”) at an average price of 846.8043 pence per Share. This purchase was made pursuant to the Trustee’s irrevocable, non-discretionary programme to purchase Shares during the period commencing 16th August 2006 to 30th September 2006.

All of the employees of Shire plc and its subsidiaries, including the Executive Directors and persons exercising managerial responsibility, are potential beneficiaries of the Trust. The Executive Directors and persons exercising managerial responsibility over Shire are therefore deemed to have an interest in the Shares held by the Trust.

For further information please contact:

Investor Relations		Cléa Rosenfeld (Rest of the World)	+	44 1256 894 160

		Brian Piper (North America)	+	1 484 595 8252

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire

Registered in England 2883758 Registered Office as above

believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

Registered in England 2883758 Registered Office as above

GRAPHIC 3 shire-logo.jpg GRAPHIC begin 644 shire-logo.jpg M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC M+B!6,2XP,0#_VP"$``("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(" M`@("`@,#`@(#`@("`P0#`P,#!`0$`@,$!`0$!`,$!`,!`@("`@("`@("`@," M`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$! M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,` M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I M*C0U-CH.$A8:' MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7 MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1 M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6& MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76 MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`#$`H0,!$0`"$0$#$0'_V@`, M`P$``A$#$0`_`/WXH`*`"@"I?W]CI-C>:GJ=Y;:=ING6L][?W][/':V=E9VT M;37-U=7$S*D%O'$CN[NP554DG`JH0G.<*=.+E.;48QBFVY-V226K;>R6XFU% M-M\JCJWM;_(_*;XR?\%/]#T+4;W1?@MX1M_%B6,O%5Q=:=H%PT99&ET MG1K01WU_:$@,EQ<3V(<$9=U M%3MWOH>76S*,6XT87M]IZ+Y):_D?--S_`,%#?VKHHXM9GM_`FE:3.(OA[X5DD2+5;KX<>`]` MU76[6$KM:YM(/%=]-]I<-\S(MU"<9V`G`.JX+R?#4INAA'B\1%7A'$XBI"FW MV;HQ5O7E?F3]?KMI.?LX]>2*;_\`)O\`,_0#0]5^-.C?#^Q^.GPO_:03]H3P M%9*NJ>)/!WB[P9X>T>]U#0K.6,:_:Z/J^A16UWH7BJPM#/*+&]A(:2`(ZGS% M#_&5:653QD\HQ^1_V)C)>Y2K4:]2<85)+]VYPJ.4:E*;LN>+T3NGH[=\76C3 M5:EB/;TUJXRBEIULU9J2[,\;^*7_``4G\8_#[XD^._`ME\*_#6HVGA'Q3K/A M^VU"Z\1ZI;7-Y!IEY);1W-Q;Q:IE_`N%QF!PF+EF%6G M+$4H5'%4H-170RC,L1@*=5U84.2TI)1;YX1F[I-I:RMN>AAZKK485+3:_0]M MKRC8*`/R=^-'_!1GQ?\`"OXK>._AW8_"_P`-ZM9^#]>FT>WU.Z\1:I:7-['% M!!*)YK>'3W2%R9B-JNPX'-?HN5\$8;,,NP>-ECZM*6)IJ;A&G!J+;:LFY)]. MQY=;,)T:LZ:I*T':]VOPL?=/[-7Q@U#XZ?"+0/B3JFB6?AV\UB\UNUDTK3[R M>^M8%TG5KO3D=+FXAB=S(EN'(*#!8@9`S7R6>Y9#)LRK8&E5E6A2C!J4HJ+? M/!2>B;2M>VYVX:JZU*-1Q46V]%ZV/>:\>[NIX;2TM89+BYN;F5(+>VMX4,DT\\TK*D,*1JS,[$*H4DD`4XQE)J,4Y2D MTDDKMM[)):MM[)!HEV2/RM_:;^,.H_M/Z3JGP;_9_N#-X'T;4HKSXO\`QEU: M[7P_\+M,TG30\QT>3Q)<8%_9B[$5S.+='-P+%(X%FB=W'Z%D&64^'ZE/,\XC MRXNI%K!X*"]IBI3GISJDOAERWC&[7+S-R<6DCR\35>)3HT-*<7>I4?NP272_ MXNV]NI\G?`#X9_"CQG\7=(^$WPRO#XMU2*RU'5_%GQN\4:-;26-A9:.D9NHO MA+\/]426TAGENIK>"#7?$<=_,JRFXALHO+7?]'G..S'"9;4S''0^K4^:,*.` MI3:DY3O9XS$0M)I).4J-!P3MRRF[ZMZS[;9Z3P&&>\97[N4 MK_G^A^1_[9/[+MO^S/XJT*30M7N]5\!>,XM0?P_/J[P?VKI=_IC6YU#1;^XA M2*.]VPW=M-#U]TUNOQW/6?^":/Q$DM/BMKWPDOIXK_P`* M^/\`P_>ZL-'GE26TB\1^&/(OHKV.W+%0TVEI=Q3`#]X+:WWY$(KSN.\"GEU' M,81=/$8*I&'.E9^SJWBXW\I\KCVO*VYKEM3EJRH_8FKV\UKMZ7_`^3_VE_\` MDX?XV>O_``LWQ?\`^G>YKZ+(?^1+E7_8+1_](1R8C_>*W^.7YG[F_L)WEGIO M[)7PYOM0N[;3[&TC\5S75Y>3Q6EI;0IXNUPO+/<3NL<,:CDL[`#N:_)>+H2E MQ'C80BY3;HI1BFVVZ-/1):W]#V\"TL+3ULES>5O>9ZZG[2_[/;ZD=(3XT?#; M[>)/*\G_`(2W1UC\S=MV"Y-R("=QQQ(>:\W^P_L9[>EK_@; M+$8>_*JT+_XD>S65[9:C:6]]IUW:W]C=1B:UO+*XBNK2XB;[LMO<0.T:T4)&A\N1V/.<\U]C@. M*.(,%@\-A<+@ZH7USJ%[`NJ1_9[> MX=)Y)@(XUW*J8.=I->#F6(S#-<=5Q.(PSCB91AS0ITIQY5&*C%\GO-726KW. MFC"EAZ<80E:";LVUWN]=#T_3?$_AK6)VM='\0Z%JERD33-;:;J^GWTZPJRHT MK0VMP[K$'D12Q&`749R17!/#UZ,>:I0J4HWM>4)15^UVDKFBE%Z1DGY)K]#E MO&GQ=^%OPW>.#QW\0?"'A.YD57BL];U[3["^D1\%9$L99Q.8B#]\1[?>NC"Y M9F&-3>#P5;$1CNZ=.3BO^WDK7\KDSJTJ7QU(T^R;2?W'::1J^EZ]I>GZUHFH M6FJZ/JMI!?Z9J6GSQW-E?65U&LMO=6MQ$2DT$D;*RNI((.17)4I5*%2=&K!T MZE-N,H25I1DG9IIZII[HM--)Q=T]4UMJ<3XO^,/PI^'\IM_&OQ&\%^%[I1DV M6L>(M+LK\`C=G[!)<_:,$'.?+YKKPV69CC%?"8&O7CWA2FX_^!)"O$MXWW;#2/$>EW6H-P3E=/2X%PPP M"J>-O'6MVN@>'='BWW%W9PWD6%A;+F2^U&X<%(K:% M6=SG`PK$=6"P6)Q^(IX3!TG5K5'I%:)+K*3VC%;N3LD14J0I1(+6G6:YJ&#;6L:<7O47=Z_SWP/U"R_9W\.:=\(-)FT7P5\-=6;4/$7@+PQ'+ M;Z=>Z!-:B(:W>:?;'=JT^DW<4=Q))/YTFR\NKERS1,X?!^;0EG=>>95%4Q6. MART\15:YHU+W]G&3^!5(MQ25E=1BM["QU!K#Q5%/3J3HR4Z;Y9 M1V^?Z,_3CP!_P50U^SC@M/B?\,+'5MJHDNM>"=3;2[AL8#3R:'K'GPM(1DE8 M[^%<]`!Q7P>,\/:+;EE^/E2[0KPYEZ<\+->K@STJ>9R6E2DG;K%V_!_YGUQX M9_;0_9$^,KZ?I?B6_P!*TN^64&PTOXK^%[6WM[>[N`L4GV75+V*\TJ"1AA2_ MVR/<`/H/FJ_"W$F4J=3#PG*%O>EA*K;:6JO"+A4?IRNQUQQF$JVC)J+6RG&W MXZK\3ZUT#P3\.],FM-=\+^$/!6GW#0F2QUG0-`T.TF:VNHMK/::CIUHK&":% MR"8Y-KJ^.0:^,A_P"1+E7_`&"T?_2$?-XC_>*W^.7Y MG?\`@?2OVC/VD/!'ACX*?#G1[W4/`?PVM[MKRSMKZ'1?#DFIZUJNHZO_`&CX MKU2]GB@O+\_:I(K2S)E,<5NTD<.Z1W/'BZF29#BZ^:8VK&GC,:G+ M>JLTM&SJR^O*G55*_P"[GHEVET:[7V9\^?M>PPG]IOXUDQ1D_P#";WA)*+G/ MV.R]J]GAIM9#E6MDJ$?SD<^+7^TUO\1[#\1(8O\`A@#]G]/+38OQ:\;%5VKM M!,OBC)`QU->9@6UQCG&MO]CH?^XC:HK8"ATM4E_[:WL=.NO(C8,AGDA:16 M165O9S;*Z6;T\+A\0W]7H8B-:I%-IS485(J%^BE*2YFM>6]M6<]"L\.YR@K2 ME%Q3VM=IW^Y?>8^G?#+XU_%(WOC#2O`7Q)\?OJ4\MQ?>*(-`UW7#J-S(Q:69 M]7>!Q>-N)R4D<+]T8`P-9X_*LNY,+4QF%P2II*-)U*=/D71*":Y?FE?<2I5J MEYQA.?G9O\3[M^-7[6?C#X8_!SX4_L^_#V>^\)^+](^&?A*W^)FN>5)9:_X; MNYM%M77PAIRRJLFDZRL+++>W&T30":*&(I(963Y'*N',-CLSS'.<9&-?#5,5 M6>%IW3IU$IO]]*VDX7TIKX96G^[E&$>=[.-U\*[/OV/DC MX1?LO_&_]H%-0\0>"O#PO-+CO)(+_P`8>*=5&G:==ZB"&N88M0O!-=:Q>(74 MRF".?87`D=6.*^DS+/\`*#K<\XJ\Z-6')+EV;Y'> M,XZV;3:5];7%5PU;#6)K M/3Y[_P`$>*+Y]VHZ[I^GIYFH:%J\QYO-5M+8&Y@NF_>3V\4XF+26X>7X+C'A MNC@HK-,OIJEAY24:]*.D:GIG*^-_&OAOX<^$]=\:^+M2BTGP[X[;Z12NY-Z) M)MDSG&E"4Y/EC!7?]?U<_,CX5>'/%'[=_P`2'^,WQ7L[G3?@#X$U:XM/AM\- MI9&^P^(-4MGVRW>K*I"7XB`B.H7/*S3$:?!BWM[@-][F%?#\'X%97ETE/.,7 M!/$XE*TJ4'M&'\M]?9QWC']Y+WI1MYM*,L;4]K47+0IOW(=&_/\`5]=MKGZN MPPQ6\44%O%';P01I#!!"BQ0P0Q*$CBBB0!8XU15554````#`K\[;;;;;;;NV M]6V]VWW/4'LH92C*&5@596`964C#*RD8*D9!!I;;:6`^$OB__P`$]?@7\3;V M]US0H=2^&'B.]D>>XN_"(MO["N;F5F>2>Y\+W:&T1V9LG["]CDY)R237U^6< M:9ME\(4:KCCJ$-$JUU426R56/O?^!J9PUL6^DHNTHO_`!)'#.E4I/EJ0=-^?Z/;[C[5_8$_:4\2_#[XD>'O MA)KNJ7.H?#KQSJ*:-IVGWLSS+X6\2WN5TF[T=I6/V.PO+S9:7-JI$1:ZCG50 M\;>9\KQCD5#&8&MF-&FJ>-P<>>4HJWM:4?C4[;RC&\HRWLG%NS5NW`8B5*I& MBW^[F[)?RM[6\GLU\SY>_:7X_:&^-@]/B;XO_35[FO?R'_D2Y5_V"T?_`$A' M+B/]XK?XY?F?MU_P3P\/V&B_LP>$[ZTB2.Z\3:UXIUS5)E0*\]VNMW6D0^8X M&7$=CI5I&N3P$XZU^4\:UIU,_P`1!OW:$*5."[+V:F_2\IR9[67Q4,-&VCDY M-].K7Y(U_P!OS2;/4OV5_B++=1*\FCR^&-7L&*@M;WL/B?2;42QD_<8VUY9+]3\,/V M9F9/VA_@D48H1\3?"(!4E2`^K6ZL,CL58@^H)K];SY6R3-5;3ZK6_P#2&>+A MM,11Z6G'\S=_:\_Y.:^-7_8[7?\`Z1V59<-?\B'*O^O$?SD/%_[S6_Q'L'Q$ M_P"3`O@!_P!E9\;?^C/%%>9@O^2QSC_L#H?^XC:I_N%#_KY+_P!N/'OV3?A; MI?Q@^/G@3P7KL(N/#IN;W7?$%H695O=)\/V4NI2Z?(4(80W=Q%:VLFT@^7EV4-G86MO8V%A;)!:6-E#%:VMK;6\86*WMK>%5C@A2-0JHBJJ@` M`8%?@DI2G-RE)RG)W>([_QA MXW\8^*]2E>74/$?B?7M9N9)"6;S-0U*YN`IR?NQHZ1@=`L8`X%?T=@Z$,+A, M+AJ:Y:="E3A%+32,4OQ>OS/EIR^G^$M#LM(2Y'C26U:_N88]U_JDL"^''$5Q?7SW-W(N]\/)J2G;V"?*G\,$_:+2$;16BT1WTLP]C3A3C15H*WQ6]7MU>IB_ M&S_@H,OQL^&/BCX:ZO\`!NPTV#Q!;6XM=6'C![Z;1M2LKN"^L-3M[9O#T/F2 MPW%NORB6/T>]?SX?3GXR?\%'_B5K/C#XD>`/V M1&94OO$OBB].G>'+>Z4']Y;Z?8RM=A3PTFIJQ&Z!"/U#@?`4L)@<9G=:/OVJ M0I_W:5*/-5:\YR]WTCYL\?,*CE4IX:/NK1OU;LONW^9^M?@'P5HGPW\%^&/` MGARW6UT;PKHUEH]BBJ$:06L06>[F"\-=75R9KF9^KRW$C'EC7YQC,55QN*KX MNL[U<1.4Y>5WHEY15HI=$DCU:<(TH1IQ5HQ5E_7GN==7,6?AG_P4DD^('@WX MVZ'KND^*O%^B^'/%W@O3S91:1XBUS3--&J:#=75EJL"6]E>Q0+C4KX:O+F)F/M*=:+C M*48RBK6;2NKWV?I]Y3_X)_\`[3-IX)\=^)/!_P`5_&FJ?V1X\MM)30=?\5Z[ M?W^G:1X@TJ6[6.QN+S5;N1-*MM1MM0D7SR4C\ZS@24C>K+7&602Q6#H8G+L) M#VF$<_:4Z-.,)3IS2O)1@DY.#BM-79MK8,!B53G*%6;2G:SDW9-=-=KW/W4@ MFAN(8I[:6*>WF19(9X)$EAEC!<)CO[4>*IPG3P4*FLX.$5_V]*21Y.'BW7I1CH^>/X.[_!%S]IDY_:(^-Q'0_$_Q@1^.L7-3D/_ M`"),J_[!:/\`Z0@Q'^\5O\Y@?]UI_]O?\`I3+O[=?_`":G\6?^O'P[_P"I?H%1PC_R4.7? MXJG_`*9J!CO]UJ_]N_\`I2/P;_9H_P"3AO@E_P!E.\(?^GBVK]>S[_D2YK_V M"UO_`$AGAX;_`'BC_CC^9O\`[7G_`"P?$3_DP+X`?]E9\;?\`HSQ17F8+_DL-/_3=#1QO_P`D_6_Z_4/_`$IBR_\`WF/^&7Y']#Y4 M,I0_=8%2.G##!_0U^*[?(^@/Y-?BOX-O_A[\2_'W@C48GMKKPWXJUO355@5W MV@O99=-NH\XW0W&G36LZ-T9)E(ZU_1F78J&,P&#Q5-WC6HTY>C<4I+U4DT_- M'RU6#I5*E-Z M_MO%>E6\=GJYU&,7.Z*:[GB-ZA(`>*]C=?E85^4Y_FG$.59KB\-_:.(I4>>4 MZ%G:+HS;E#ETM:*?(^SBTSV<-1PM6C"2I1NE:7E);W]=STCXC?L__L:?"CP; MK7CKQK\)?`6E:!H5J]Q._P#9S&ZO)]I^S:9IEL]XAO=4NI0(H+=6!=W&2JAF M7AP.<<3YABJ6#PF8XB=:J[)MX(M;>/2]4T^==3M M]7GN$\1RFVM[`V9O))1')L6V+;6Q@^]F.7\8X/`8NOC,XA]5A2E[6/MV^:$E MRN"7LU=SYN5*ZNWNCGI5,#*I"-.@U-M^_3<_63)]37YR>H?D]^VK^R M/\6?&'Q2LOCI\&H8->U1+;0'U/P\+RTL=:T[6/"YC&EZOHXU"2*VU&V>&WLP M]L9DE62W)595E(C_`$7A7B3+L)E\LHS-NA3O4Y*G*W"4*OQPGRIRBTW*TK-6 M>MFM?+QF$JRJJM1U>EX[-..S5[)^A]%?#_\`:8^,=UIME9?$C]DSXT:9XCCB MC@O;WPI8:!J.@7UT@VRW5M_:^OZ>^G0R,-WE223A-V%FD`R?$QF0Y7"IAC4:_\#K*BEZJ,O1G0IU'M2Y%_>DE^$>;]#F?CM\`=!_:$^&W_``A? MCB>WM->M7.I:#XHT:S>-_#NOB-XTNK*VNKB22?3I(G\BYM)9\7$>3NCD6-X= M\HSBMDF.^M8--T7[M2E.7\2FW>TFDDI7UC)+W7W5TYKX>->GR3TE'5-*UGZ= MNZZGX(?%O]D#X\_!Z]O(]9\#ZEXE\/0._P!G\6^#+.Z\0:)=6P9E2:X@LX7O M=(=E&3#>V\6,X#N,,W[#EO$N3YC"+HXN.&K=:-:2I33ZI-M1GZPD[]EL>%5P ME>BW>#%6OB3QMH41TRQ\1>-=#@CRATRTUKQ%I4,>>#&;"&ZB M6/J1M\L=>E>O*AA*CYY4*%5_S.%.3_\``FG^9@I3CHI2BNR;7X'4^#/@_P#% MWXH:F(?!W@#QGXIO;N1#-J/]EZ@MF#(0HGU#7]46*TACYR9)[H<>M<^*S++< MOIWQ.,H8:,=H<\>;TC3A>5_)1+A1JS=H4Y/SLTOFWHC]N/V,_P!BY?@&\OC_ M`,?7-AJWQ/U*P>PM+73V\_2?!NFW84WMK9W;HIO]7N5"Q7%XBI&D:M#!N222 M2;\IXHXH_M=+!8*,J6`IRYFY>[.M)?"Y1^S".\8[M^]+5)+V<'@_J_OSM[1J MR2VBGO;S[O[C\K/VB/A#\6=4^/'QAU/2OA=\0]1TV_\`B+XJN[#4+#P;X@N[ M&]M9]5N'AN;2Z@L&CN+>1"&61&96!!!(K]"R3,LMI9/EE.>88:G.&&I*495Z M<91:@KIIR3375,\O$4:OMZSC2G;GE:T7;?T/VF_8@T/6O#7[,OPYT;Q#H^J: M!J]G_P`)+]JTK6;"YTS4;7SO%6LSP_:+*\BCEA\R&2.1=R#S@HN.&IQDG%KFT:L_B?0N?MI MZ+K/B']F7XH:-X?TG4M]LM!6STK1[&YU'4;MHO%6ASRK;65I&\LQ2&.21 M@B'"QLQX!-1PM5I8?/LOJ5JD:%*$JEY3DH1C>E42NVTE=M+S;#&1;PU6,4V] M+)+7XET1^)G[._PA^+.D_'GX.ZGJ?PN^(>F:;I_Q&\*7=]J%_P"#?$%G8V5K M#JMN\]S=W4]@L=M;QH"S2.RJH!)(%?JN=YEEL\GS.G2S##3G+#5E&,:U-R;< M'9**E=M]$MSQL/1JQKT6Z4XI37V6DM?0W/VJ?A+\5=9_:+^+^K:+\,OB!JVE M7WC&ZN+#4M,\(:]?:?>0-:V:K/:7=M8O%<1%E8!T9AD'GBLN'LQRZCDF64JF M/P]*I"BE*$JU.,HN[T<7)-/U16*HU?K%5QI2MS:-1=OR/5O'OPS^)%Q^PW\# M?#=K\/O&UQXBTWXH>,+W4=`@\+ZU)K.GV=Q)XD,%W>Z8EF;BUMI1-%LDDC56 M\U,$[AGSL'C\##BS-JSQM"-">$HQC4=6"A*2]E=1ES]T&?L`_#+XD^%_VD=#U?Q+\/?&WAS28O"GB^"34]<\+:UI.G MQS7%A$L$+WE[9QQ)+(P(12P+$8`-/C''X&MD56EA\;0JU/;46H4ZL)RLI.[Y M8R;LNN@8"E4AB8N5.4$HRU<6EL?O37X^>X?G?^VE^Q=+\QL/B=I MUC'8ZCIM]*MEIWC73;52+*&6](V6&NVJ$Q07,P\J6(I#.T:Q1R1_:\+<4+)T M\#C5*6`G+FC**O*A)_$U'[5.6\HK5.\HIMM/S\9@_:_O*5E46EME)+\GV9^- MW]D?M"?L_P"OW(AL/BE\*]1RXC#2T4Z3\KK\M&+=?\-#_ M`!]U>RL[Y/BO\5-4A?9807L.OZQ;6+/\K/'Y\:V&EK@_/,QA`&2[`9I1_L7) MJ4I0^J9;3?Q.+IP;^Y\\O):^2#_:*S2?/4:VW=OT1^QG[$G[&MY\#?M/Q'^) M`LIOB7JM@^GZ9I-G+'>6G@K2+K:U[$;U,QW>O7@5(YY8"8H85,,4D@FE9OS+ MBOB>.:\N!P/-'`4Y[?\``/\`T(54=P&V7^H_X$U$MP18J0"@#__9 ` end EX-99.2 4 dp03521_ex9902.htm

	Exhibit 99.02
Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com

Press Release

18 September 2006

Shire plc ("Shire")

Purchase of Shares by Employee Benefit Trust

Shire has been notified that on 18 September 2006, the Shire plc Employee Benefit Trust (the “Trust”) purchased 135,000 Ordinary Shares of Shire plc (“Shares”) at an average price of 852.6779 pence per Share. This purchase was made pursuant to the Trustee’s irrevocable, non-discretionary programme to purchase Shares during the period commencing 16th August 2006 to 30th September 2006.

All of the employees of Shire plc and its subsidiaries, including the Executive Directors and persons exercising managerial responsibility, are potential beneficiaries of the Trust. The Executive Directors and persons exercising managerial responsibility over Shire are therefore deemed to have an interest in the Shares held by the Trust.

For further information please contact:

Investor Relations		Cléa Rosenfeld (Rest of the World)	+	44 1256 894 160

		Brian Piper (North America)	+	1 484 595 8252

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire

Registered in England 2883758 Registered Office as above

believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

Registered in England 2883758 Registered Office as above

-----END PRIVACY-ENHANCED MESSAGE-----